People living with diabetes now have the option to use Abbott’s next-generation FreeStyle Libre 2, an integrated continuous glucose monitor. Abbott received the Food and Drug Administration’s ...

Randomized clinical trial of Abbott's FreeStyle Libre 2 system compared to self-monitoring of blood glucose (SMBG) shows FreeStyle Libre 2 leads to significant reductions in glycated hemoglobin (HbA1c ...

SAN FRANCISCO--(BUSINESS WIRE)--Today, Nutrino, (www.nutrino.co) announces the collaboration with the LibreLink 1, 2 application, designed for Abbott’s FreeStyle Libre Flash Glucose Monitoring system.

Real-world data showed the use of a continuous glucose monitoring system was able to substantially reduce A1c levels among people with Type 2 diabetes regardless of whether they were taking insulin.

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...

Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading sensor-based glucose monitoring technology, is associated with significant reduction in ...

The FreeStyle Libre 3 glucose monitoring system (Abbott) has been granted a CE mark for use by people with diabetes in the countries of the European Union (EU). The next-generation FreeStyle Libre 3 ...

Abbott's FreeStyle Libre Flash Glucose Monitoring System works by inserting a tiny sensor wire below the surface of your skin. The wire needs 12 hours to start up, but once it's ready, you can simply ...

The US Food and Drug Administration (FDA) has cleared the FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system for adults and children ages 4 years and older with diabetes. The ...

ABBOTT PARK, Ill., Feb. 16, 2016 /PRNewswire/ -- Today, Abbott (NYSE: ABT) announced that it has received approval from the Therapeutic Goods Administration (TGA) in Australia for its FreeStyle® Libre ...